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Objective: Dopamine supersensitivity psychosis (DSP) is considered to be one cause of treatment-resistant
schizophrenia (TRS). The authors investigated the efﬁcacy of risperidone long-acting injections (RLAI) in patients
with TRS and DSP.
Method: This is a multicenter, prospective, 12-month follow-up, observational study that included unstable and
severe TRS patients with and without DSP. 115 patients with TRS were recruited and divided into two groups
according to the presence or absence of DSP which was judged on the basis of the clinical courses and neurolog-
ical examinations. RLAI was administered adjunctively once every 2 weeks along with oral antipsychotics. We
observed changes in scores for the Brief Psychiatric Rating Scales (BPRS), Clinical Global Impression—Severity
of Illness (CGI-S), Global Assessment of Functioning Scale (GAF), and Extrapyramidal Symptom Rating Scale
(ESRS) during the study. Of the assessed 94 patients, 61 and 33 were categorized into the DSP and NonDSP
groups, respectively.
Results: While baseline BPRS total scores, CGI-S scores and GAF scores did not differ, the ESRS score was
signiﬁcantly higher in the DSP group compared with the NonDSP group. Treatment signiﬁcantly reduced
BPRS total scores and CGI-S scores, and increased GAF scores in both groups, but the magnitudes of change
were signiﬁcantly greater in the DSP group relative to the NonDSP group. ESRS scores were also reduced in
the DSP group. Responder rates (≥20% reduction in BPRS total score) were 62.3% in the DSP group and
21.2% in the NonDSP group.
Conclusions: It is suggested that DSP contributes to the etiology of TRS. Atypical antipsychotic drugs in
long-acting forms, such as RLAI, can provide beneﬁcial effects for patients with DSP.
Clinical trials registration: UMIN (UMIN000008487).
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/)., Graduate School of Medicine,
shi, Chiba 260-8670, Japan.
ara).
. This is an open access article under1. Introduction
Antipsychotics are usually effective against the acute symptoms of
schizophrenia (Freedman, 2003), especially for the ﬁrst episode of thethe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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of the patients relapse into psychotic episodes even after attaining
amelioration of their preceding episodes (T.S.S.R. Group, 1992; Robinson
et al., 1999). This progressive clinical course is thought to be part of the
disease process, indicative of continuing brain dysfunction, while other
factors, including effects of the antipsychotic medications being used for
treatment, are also thought to play a role in this clinical progression
(Zipursky et al., 2013).
Dopamine supersensitivity psychosis (DSP) was ﬁrst identiﬁed in
the 1970s (Chouinard et al., 1978), and from 22–43% of all patients
with schizophrenia suffer from this psychosis (Chouinard et al., 1988;
Chouinard, 1991). The features of DSP include development of tolerance
to antipsychotic therapeutic effects, such that even high doses of anti-
psychotics no longer control symptoms, and an acute exacerbation of
symptoms on discontinuing antipsychotics or even after minor stress
(Kirkpatrick et al., 1992; Moncrieff, 2006; Chouinard and Chouinard,
2008; Fallon and Dursun, 2011). It is thought that these features may
be an integral factor in the development of relapse vulnerability and
treatment-resistant psychosis. It has been estimated that more than
half of treatment-resistant schizophrenia (TRS) cases may be related
to DSP (Iyo et al., 2013). The mechanisms underlying DSP are not fully
understood yet, but may be closely associated with the increased densi-
ty of dopamine D2 receptors (DRD2), which increases behavioral sensi-
tivity to dopamine, following chronic treatment with antipsychotics, as
reported in animalmodels (Inoue et al., 1997; Samaha et al., 2007, 2008;
Tadokoro et al., 2012; Iyo et al., 2013). DSPmay be also acceleratedmore
profoundly by ﬁrst-generation antipsychotics than second-generation
antipsychotics (Correll et al., 2004; Li et al., 2009; Iyo et al., 2013).
Thus, although up-regulation of dopamine D2 receptors (DRD2), in-
duced by antipsychotic therapy blockade,may underlie DSP, an effective
treatment strategy for patients with DSP has yet to be established.
We have recently put forward a hypothesis on the mechanisms
and treatment strategy for patients with DSP (Iyo et al., 2013). Brieﬂy,
optimal DRD2 occupancy by antipsychotics is higher in patients with
DSP, leading to the need for higher doses of antipsychotics to achieve
a clinical result. However, in these cases, greater quantities of the drug
may be eliminated relative to standard doses, as the elimination half-
life of the drug may remain the same, independent of the dose load.
This greater level of elimination causes drug concentrations to ﬂuctuate
across both upper and lower lines of the optimal therapeutic window,
particularly for high-dose oral antipsychotics with a relatively short
half-life. Furthermore, endogenous dopamine may bind to larger
numbers of DRD2, producing enhanced effects. Therefore, in patients
with DSP, antipsychotics administered in a form that will yield stable
blood concentrations within optimal therapeutic ranges may be of
greater use in improving severe and unstable symptoms than the
usual tablet formats.
Risperidone long-acting injection (RLAI) was the only long-acting
injectable second-generation antipsychotic drug available in Japan at
the start of this study. The width between peak and trough blood con-
centration of RLAI is 32 to 42% smaller than that of oral-risperidone
(RIS) using equivalent doses (Eerdenkens et al., 2004). We recently
reported that RLAI treatment successfully ameliorated unstable positive
symptoms in two DSP cases with TRS (Kimura et al., 2013). Here, we
aim to explore the hypothesis that an atypical long-acting agent can
prove clinically efﬁcacious in TRS patients with DSP.
2. Methods
2.1. Study design
This is a multicenter, observational study, with a prospective design
for assessing clinical outcomes in patients with TRS. The primary objec-
tive is to verify the effectiveness of RLAI, that is, the percent change in
total BPRS during a 12-month follow-up of the patients. We recruited
patients with TRS, who had been selected to receive RLAI by theirphysicians in clinical setting, from May 2010 to September 2011 and
divided them into two groups, deﬁned by the presence or absence of
DSP. The assessment of DSP in patients was evaluated by two experi-
enced psychiatrists (H.K. and N.K.). Physicians were given no speciﬁc
instructions for administering RLAI and oral antipsychotics, although
they were instructed to give oral antipsychotics for at least 3 weeks
following RLAI initiation and to inject RLAI every two weeks, in accor-
dancewith the approved labeling. Physicians were allowed to prescribe
antiparkinsonism agents, benzodiazepines andmood stabilizers at their
own discretion. Brieﬂy, physicians were encouraged to treat partici-
pants so as to achieve maximal clinical effect with minimal side effects.
This study was approved by the ethics committees of all participating
research facilities. Written informed consent was obtained from all
participants after providing them with a full explanation of the study.
2.2. Patients
Patients were eligible for study inclusion if they had a diagnosis of
schizophrenia or schizoaffective disorder according to the Structured
Clinical Interview for DSM-IV (First et al., 1995). We applied the broad
eligibility criteria (Juarez-Reyes et al., 1996) for TRS in the present
study, as follows. A patient who scored below 60 in the Global
Assessment of Functioning (GAF) at least one year before entering
this study and who met either or both of the following two criteria.
1) Non-responder criterion: failure to respond to at least two anti-
psychotics belonging to two different chemical classes, at dosages
equivalent to or greater than 600 mg/day chlorpromazine equiva-
lent (CPZeq) for at least 4 weeks. 2) Intolerance to antipsychotics
criterion: TD with moderate or greater severity assessed by ESRS,
causing profound distress to the patient. Exclusion criteria for this
studywere: previous treatment with RLAI and/or clozapine, a history
of illegal drug use or substance dependence, the presence of any
other AxisIdisorders except for schizophrenia or schizoaffective
disorder, mental retardation, pregnancy or any severe physical disease,
and the presence of poor medication adherence.
2.3. Measurements
2.3.1. Dopamine supersensitivity psychosis
Presence of DSP was deﬁned using criteria proposed by Chouinard
(1991). That is, 1) withdrawal psychosis: acute relapse or exacerbation
of psychosis appearing after a dose reduction or discontinuation of
antipsychotics, within 6 weeks for oral medication or 3 months for
intramuscular medication. This episode must be observed within the
last 5 years. Or 2) developing tolerance to antipsychotic effects: This is
deﬁned as when an acute relapse or exacerbation of psychosis occurs,
independent of a dose reduction or discontinuation of antipsychotic
therapy, which cannot be successfully controlled by a 20% increased
titration of drug. Or 3) psychotic symptoms which are new to the
patient, or of greater severity, occurring immediately after a decrease
in drug dosage. Or 4) a history or presence of TD. Based on available
information from medical records and hospital staff, if at least one of
the listed items above was present, the participant was diagnosed as
having a history of DSP. The inter-rater reliability between the two
assessors (H.K. and N.K.) was .88. If non identical diagnoses were
reached, a consensus-based judgment by these two assessors was
applied to the case.
2.3.2. Clinical measurements
The patients were evaluated at baseline (T0), and then after three
(T1), six (T2), nine (T3), and twelvemonths (T4). The primary outcome
measure was the percent change in the Brief Psychiatric Rating Scale
(BPRS: 18 items, 1–7 scale for each item: Overall and Gorham, 1962)
score from T0 to T4. The secondary outcome measures were recorded
changes every three months in GAF and Clinical Global Impressions—
Severity of Illness (CGI-S). For analyses of patient numbers showing a
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showing a reduction of greater than 20% from baseline. Extrapyramidal
symptoms (EPS) were evaluated using the Extrapyramidal Symptom
Rating Scale (ESRS: 0–257 point that is summed from all of the factors
including the last four sections of clinical impressions: Chouinard
and Margolese, 2005). Compliance with treatment medication was
monitored using by both a self-rating visual analog scale for patient
and objective observation by their respective physicians, which
rated medication administration from 0 to 100% (Garﬁeld et al.,
2011). If these measurements differed from each other by no more
than 25%, the mean of both values was used as the patient's adherence
rate. To reliably evaluate with these measurements, physicians on the
study underwent several rounds of assessment training.
2.4. Statistical analysis
All analyses were conducted using SPSS, version 19.0 (IBM, NY, US).
Data analyses were conducted on an intent-to-treat basis including all
dropout cases (Fig. 1). Analyses for the primary efﬁcacy measure were
performed using a mixed-effects model repeated-measures analysis
(Gueorguieva and Krystal, 2004). Treatment group, time and each
time-by-group interactionwere included as ﬁxed effects, while baseline
scale scores and agewere included as covariates. Thewithin-subject fac-
tor was considered as a random effect. Compound symmetry was used.
Logistic regression analyses was also performed to look at the effect
of treatment group on the outcome measure of treatment response or
nonresponse at T4, with age, sex, duration of illness, baseline BPRS
and ESRS scores, treatment adherence and the presence or absence of
DSP included as items. Continuous and categorical variables were
compared by independent t test and chi-square test, respectively. A P
value of .05 was set as the threshold of signiﬁcance.
3. Results
3.1. Patient characteristics and analysis of drop-out cases
Of the 115 patients screened, 21 patients were excluded due to
meeting exclusion criteria, being lost to follow-up or refusing to par-
ticipate before the evaluation for DSP, yielding a ﬁnal analytic sample
of 94 patients (Fig. 1: DSP group: N = 61, NonDSP group: N = 33).Fig. 1.Overview of participant ﬂow. Initially, 115 patients were screened. Of these, 21 were lost
of consent before evaluation of DSP status, yielding a ﬁnal analytic sample of 94 patients (DSPBaseline demographics and clinical characteristics were similar
between the two groups (Table 1). The BPRS positive symptoms
score showed no difference between the two groups, whereas the
BPRS negative symptoms score and ESRS score in the DSP group
were signiﬁcantly higher than those of the NonDSP group (P b .001).
A total of 75 patients (79.8%) completed the 12-month RLAI treatment.
There was no signiﬁcant difference in the dropout rates between the
two groups: 14.8% (N = 9) in the DSP group and 30.3% (N = 10) in
the NonDSP group (P N .05). Seven DSP and 7 NonDSP patients left
the study due to an exacerbation of psychotic symptoms. Two DSP
patients discontinued due to dystonia and akathisia, and 3 NonDSP
patients discontinued due to constipation, hyperglycemia and dystonia.
3.2. Treatment with RLAI and other oral antipsychotics, medication
adherence
The mean daily total CPZeq-dose of oral antipsychotics at baseline
was about 1000 mg in both groups (Table 1). The subjects received
quite variable types and combinations of antipsychotics with variable
dose ranges. The primary types of antipsychotics used in the present
patients were risperidone (1–18 mg), olanzapine (4–40 mg) and
quetiapine (200–825 mg). Percent rate of RLAI patients receiving dose
of 25 mg, 37.5 mg and 50 mg at T4 was 13.5%, 19.2% and 67.3% respec-
tively in the DSP group, and 13.0%, 21.7% and 65.2% respectively in
the NonDSP group. For daily oral antipsychotics dosing (CPZeq-dose),
the mean (±SD) doses at T4 were 605 (791) mg/day and 471 (421)
mg/day in the DSP group and the NonDSP group, respectively. There
was a signiﬁcant main effect for Time (F = 9.70, P b .001), but
no main effect for Group (F = 0.37, P N .05) or for an interaction of
Time × Group (F = 0.07, P N .05). There was no signiﬁcant difference
in the total amount of daily oral antipsychotics and RLAI dose (CPZeq),
at T4, between the two groups nor were there signiﬁcant time effects
during the treatment between the groups (Table 2).
Mood stabilizers were prescribed for 19 of 61 DSP patients and 14
of 33 NonDSP patients. Among them, 13 DSP patients and 9 NonDSP
patients took sodium valproate at T0: their distributions and their
mean doses did not differ between the two groups. These doses tended
to be lower during the study, though not signiﬁcantly, in both groups
(data not shown). Regarding benzodiazepine and antiparkinsonism
agents, none of the groups showed any signiﬁcant differences either in
baseline doses or in dose changes between T0 and T4.to the study due tomeeting the exclusion criteria, being lost to follow-up, or a withdrawal
group: N = 61, NonDSP group: N = 33).
Table 1
Characteristics of eligible participants.
DSP group
N = 61
NonDSP group
N = 33
All patients
N = 94
Statistical valuec
Age (years) 43.6 (14.7) 48.5 (11.1) 45.4 (13.7) N.S.
[Age range] [18–69] [26–69] [18–69]
Sex (male/female) 30/31 17/16 47/47 N.S.
Duration of illness (years) 20.4 (12.5) 21.2 (11.9) 20.7 (12.3) N.S.
Inpatient/outpatient 32/29 14/19 46/48 N.S.
Non-responder/intolerance to antipsychotics 57/4 33/0 90/4 N.S.
Diagnosis
Schizophrenia 58 29 87
Schizoaffective disorder 3 4 7
DSP type
Withdrawal psychosis 41 – 41 –
Tolerant to antipsychotics 35 – 35 –
Relapse with great severity 27 – 27 –
Tardive dyskinesia 24 – 24 –
Antipsychotics dose
(CPZeq: mg)
1084.6 (741.4) 960.1(444.1) 1040.4 (651.7) N.S.
[Dose range] [0–4512.5] [200–2050.0] [0–4512.5]
BPRS
Total score 63.0 (18.6) 58.5 (15.7) 61.4 (17.7) N.S.
Positive symptom scorea 17.0 (5.5) 16.7 (5.6) 16.9 (5.5) N.S.
Negative symptom scoreb 13.0 (3.8) 10.8 (3.1) 12.2 (3.7) P = .004
CGI-S 5.5 (1.1) 5.3 (1.0) 5.4 (1.0) N.S.
GAF 30.9 (13.1) 32.7 (11.4) 31.5 (12.5) N.S.
ESRS 34.2 (32.4) 17.8 (17.5) 28.5 (29.1) P = .001
Adherence 89.2 80.6 86.3 N.S.
Data are mean (SD) [absolute range]. Unless otherwise noted, differences between the DSP and NonDSP groups were not statistically signiﬁcant (P N .05).
Abbreviations: DSP = dopamine supersensitivity psychosis, CPZeq = chlorpromazine equivalent, BPRS = Brief Psychiatric Rating Scale, CGI-S = Clinical Global Impression Severity,
GAF = Global Assessment of Functioning, ESRS = Extrapyramidal Symptom Rating Scale.
a The summed scores for conceptual disorganization (#4), suspiciousness (#11), hallucination (#12), and unusual thoughts (#15).
b The summed scores for emotional withdrawal (#3), motor retardation (#13), and blunted affect (#16).
c Statistical result of each comparison between theDSP andNonDSP groups. Student's t test is applied for continuous variables and the chi-square test is applied for categorical variables.
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administered visual analog scale at T0, T2 and T4, was 89.2%, 92.2% and
90.0% in theDSP group and 80.6%, 86.8% and 88.4% in theNonDSP group,
respectively (Table 1). The difference between the self-administered
visual analog scale by each patient and assessment ofmedication adher-
ence rate by his/her physician was within 25% in all patients. Through-
out the study period, all patients received RLAI procedures at over 90%
of the scheduled visits (once every two weeks).
3.3. Primary outcome measures
Mixed-model analysis of the percentage change in BPRS total scores
from baseline to 12 months showed signiﬁcant improvement in DSP
relative to NonDSP patients. This difference was observed from T1 to
T4 at each time point analysis (Fig. 2A and Table 2). Average BPRS
total scores in both groups were also signiﬁcantly decreased after the
12-month treatment period (P b .05). Based on percentage changes inTable 2
Follow-up assessment outcomes over all time points up to 12 months.
BPRS total score DSP group
Score at T4 Percentage change in
BPRS total score 42.1 (18.0)b 33.0 (19.9)
Positive symptom score 11.3 (5.5)b 33.3 (22.9)
Negative symptom score 8.8 (3.9)b 31.7 (24.0)
CGI-S 3.8 (1.4)b
GAF 49.2 (16.9)b
ESRS 19.2 (23.6)b
Antipsychotics dose (CPZeq: mg) 1034.7 (823.4)
Adherence (%) 90.0
Data are mean (SD). T4 indicate time points at 12 months. The numbers of patients at T4 were
Abbreviations: N.S. = not signiﬁcant.
a P values for the comparison in % change score or each measurement score between th
mixed-effects model with three ﬁxed effects (time, treatment group, and time-treatment
b P b .01 comparisons in each score between baseline (T0) and T4 within the group.BPRS positive and negative symptom scores, DSP patients showed sig-
niﬁcantly greater improvements compared with NonDSP patients
(Fig. 2B, C and Table 2).
Furthermore, we analyzed the percentage BPRS changes only among
inpatients with DSP (N = 32) whose adherence was approximately
100%, because they took their medication under staff observation. The
results revealed that BPRS scores at T0 and T4 were 68.1 ± 20.3 and
53.6 ± 25.2, respectively, indicating change of more than 20%, suggest-
ing that amelioration in the DSP group was not caused simply by
improvement of medication adherence.
3.4. Secondary outcome measures
Themean CGI and GAF scores signiﬁcantly improved in both groups.
The CGI and GAF scores signiﬁcantly decreased and increased respec-
tively, in each DSP and NonDSP group (P b .05). The improvements
during treatment were signiﬁcantly more pronounced in the DSPNonDSP group
score Score at T4 Percentage change in score P valuea
44.3 (16.5)b 17.0 (20.5) b .01
12.1 (5.2) 16.7 (27.7) b .01
8.6 (2.7)b 16.6 (22.2) b .01
4.3 (1.3)b b .01
42.5 (14.9)b b .01
18.1 (16.7) N.S.
870.5 (466.9) N.S.
88.4 N.S.
52 in the DSP group and 23 in the NonDSP group.
e DSP and NonDSP groups. The treatment comparison was a liner contrast based on a
group interaction). The within-subject factor was considered as a random effect.
Fig. 2. Percentage change in BPRS total, positive and negative symptom scores over
time. The red and blue lines indicate changes in the DSP and the NonDSP group,
respectively. Error bars indicate standard error of the mean. Percentage changes in
BPRS total, positive and negative symptom scores were analyzed using mixed effects
model repeated-measures analysis. There were signiﬁcant differences in A) total,
B) positive and C) negative symptom scores between the DSP and NonDSP group
(P b .01). ⁎P b .05 and ⁎⁎P b .01 represent signiﬁcant improvement in each group
and the percentage change in BPRS score from baseline respectively.
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signiﬁcant difference between the two groups at the end of the study
(Table 2). However, there were signiﬁcant reductions in this valueTable 3
Multiple logistic regression model of factors associated with responders.
Partial regression coefﬁcient
Presence of DSP 1.93
BPRS at baseline
Total score −0.02
Positive symptom score 0.01
Negative symptom score 0.07
ESRS b−0.01
Sex −0.23
Age −0.02
Duration of illness b0.01
Adherence 0.19from T0 to each subsequent time point in the DSP group, whereas
there was no change in the NonDSP group. Furthermore, the TD score
of ESRS was signiﬁcantly lower in the completers of the DSP group. On
the other hand, no patients in the NonDSP group exhibited new TD dur-
ing the study period.
Responder rates were 62.3% (N= 38) in the DSP group and 21.2%
(N = 7) in the NonDSP group, indicating a signiﬁcant difference
(χ2 = 14.5, P b .001) between the two groups.
Logistic regression analysis revealed DSP as the only factor signiﬁ-
cantly related to RLAI response (odds ratio = 6.90, P b .01: Table 3).4. Discussion
To our knowledge, this is the ﬁrst study to investigate the efﬁcacy of
a 12-month RLAI treatment regime in patients with TRS and DSP. The
treatment yielded signiﬁcantly greater improvement in psychiatric
symptoms and global functioning in DSP patients compared with DSP-
free patients. DSPpatients also showed a higher response rate (62%) rel-
ative to those without DSP (21%). Multiple logistic regression analyses
revealed that the presence of DSP greatly contributed to clinical im-
provements in this study. Furthermore, at the end of the study, patients
who received high antipsychotic doses (both oral antipsychotics and
RLAI), took comparable daily oral antipsychotic doses at baseline prior
to RLAI initiation. These results imply that adjunctive RLAI treatment
with a gradual reduction of oral antipsychotics can help to promote a re-
markable improvement in DSP patients. Unsurprisingly, DSP patients
showed severer EPS at baseline, including TD, a neurological DRD2 su-
persensitivity (Sasaki et al., 1995a, 1995b) and an important criteria in
the diagnosis of DSP (Chouinard, 1991; Fallon and Dursun, 2011). In
the DSP group, the possibility that RLAI treatment lessens severe EPS
was observed. Taken together, our ﬁndings suggest that achieving and
maintaining stable therapeutic blood levels of antipsychotics could im-
prove symptoms in patients with severe and treatment-resistant DSP,
supporting our original hypothesis (Iyo et al., 2013). In addition, the de-
velopment of other long acting injectable antipsychotics, such as other
classes of atypical antipsychotics or longer-acting forms, may be desir-
able for the treatment of DSP.
The ESRS score and the TD score were lower overall in the DSP
group, whereas no change was observed in the NonDSP group. When
we consider that the mean of the total chlorpromazine equivalent
doses was not different between the entry (T0) and the end (T4) of
this study, we can infer that the reduced ﬂuctuation of plasma antipsy-
chotic levels contributes not only to the stabilization of psychosis but
also to the reduction in antipsychotic-induced EPS and TD, which can
be considered neurological manifestations of dopamine supersensitivity.
In this study, DSP patients exhibited signiﬁcant negative symptoms
at baseline, which improved remarkably during treatment. Antipsy-
chotics are capable of improving negative and depressive symptoms,
depending on the extent to which positive symptoms and EPS are
reduced (Tandon, 2011). In DSP patients, the dramatic improvement
in positive symptoms and EPS plays a contributory role in the improved
negative symptoms and general functioning.P value Odds ratio 95% conﬁdence intervals
b .01 6.90 2.19–21.80
.45 0.98 0.92–1.04
.87 1.01 0.86–1.19
.46 1.07 0.90–1.28
.79 1.00 0.98–1.02
.63 0.95 0.31–2.05
.58 0.99 0.94–1.04
.94 1.00 0.94–1.06
.38 1.20 0.80–1.82
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ble reasonmay be sub-optimal dosing, with the combined RLAI and oral
antipsychotic treatment. If the total dosageswere too low to achieve op-
timal receptor occupancy, or if the elimination half-life of the oral drugs
was too short to maintain optimal occupancy, RLAI therapy may not be
sufﬁcient to control disease symptoms. In Japan, the maximum dose of
RLAI is limited to 50 mg/2-week, which is estimated to produce an oc-
cupancy range of 65.4 to 74.4% (Remington et al., 2006), corresponding
to the optimal range for patients with a ﬁrst schizophrenic episode
(Kapur et al., 2000). Further studies are needed to clarify the accuracy
of this data and its validity for subsequent episodes.
The study treatment provided only limited efﬁcacy for NonDSP
patients. In this group, positive symptoms failed to show signiﬁcant
improvement, while the negative symptoms showed only slight sig-
niﬁcant improvement. Reports highlight that patients with deﬁcit
syndrome (Galderisi and Maj, 2009) respond poorly to antipsychotic
treatment and show profound continued negative symptoms. It is
possible that there were a signiﬁcant number of patients with deﬁcit
syndrome within our NonDSP cohort. That said, there may be patients
with other types of confounding factors, as schizophrenia is known
to be a heterogeneous disease (Tandon et al., 2009; Insel, 2010;
Kanahara et al., 2013). Clozapine is known to improve symptoms in
deﬁcit syndrome (Rosenheck et al., 1999; Kelly et al., 2010). It is highly
possible that in these patients, the mechanistic action is not via block-
ade of DRD2, but by modulation of other sites, such as the N-methyl-
D-aspartate receptor, a candidate target of clozapine in the treatment
of schizophrenia (Hashimoto, 2011; Miyamoto et al., 2012). However,
further studies are needed to fully explore this point.
To date, there are two previous reports on clinical trials using RLAI in
TRS (Procyshyn et al., 2010; Volonteri et al., 2010), although in these
studies, patients were switched from other antipsychotics to RLAI. This
differs from our study where RLAI was used adjunctively. In one study,
a 6-month RLAI treatment achieved a 60% response rate in treatment-
resistant patients with severe symptoms (Volonteri et al., 2010). The
other study failed to show an advantage for RLAI (Procyshyn et al.,
2010). Neither of these studies made special reference to DSP, nor did
they report on the dosages of antipsychotics in use before patients
entered the study. Therefore, it is unknown what percentage, if any of
their study participants suffered from DSP and whether the doses of
RLAI were high enough to improve symptoms in these studies.
As with all reports of this nature, there are some limitations to this
study. First, thiswas a relatively short termobservational study, because
our aimwas to maximize efﬁcacy of the RLAI regime to effect improved
conditions for TRS patients. A randomized, controlled study with a
longer follow-upduration is needed to conﬁrmour observation. Second,
we didn't directly measure D2 receptor occupancy or the ﬂuctuation of
plasma levels of antipsychotics. Therefore, further studies, including
direct measurements of these parameters, are needed to conﬁrm
our hypothesis on the mechanisms underlying DSP and treatment of
patients with DSP. Third, the medication adherence level may affect
the results to some extent in this study, since it has been suggested
that most patients actually are under partial adherence (Oehl et al.,
2000), especially patients with TRS, like our participants. Therefore,
we evaluated our patients' adherence using self-reported data and the
observations of their physicians. The results conﬁrmed no differences
between these two reports, although we didn't use pill-count methods.
Furthermore, we analyzed BPRS scores and their changes only among
the inpatients with DSP, whose adherence rates could be considered
almost 100%, and the results were similar to those obtained by the anal-
ysis of all patients with DSP. In this light, we consider that the present
results on the improvement of symptoms were not likely attained
simply by improvements in medication adherence alone.
In conclusion, our study demonstrated that adjunctive RLAI
treatment signiﬁcantly improved psychotic symptoms and global
functioning in TRS patients with DSP. While clozapine is considered
the standard antipsychotic drug of choice for TRS (Kane et al., 1988),it is associated with serious adverse events, such as agranulocytosis
and diabetes mellitus (Fakra and Azorin, 2012). This study suggests
that therapeutic regimes using antipsychotics with long elimination
half-lives may prove suitable alternatives to clozapine for this cohort
of patients.
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